financetom
Business
financetom
/
Business
/
Hormel Foods forecasts annual sales, profits below estimates on tepid demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hormel Foods forecasts annual sales, profits below estimates on tepid demand
Dec 4, 2024 5:52 AM

Dec 4 (Reuters) - Hormel Foods ( HRL ) forecast annual

sales and profit below estimates on Wednesday, hurt by slowing

demand for its snacking and meat products, including its

Jennie-O Turkey brand.

Shares of the company fell nearly 4% premarket after Hormel

also posted fourth-quarter results in line with Wall Street

expectations.

Jennie-O Turkey is one of Hormel's key brands, contributing

about 12% to sales in 2022. However, demand for turkey, which is

more expensive than chicken or pork, has taken a hit as

consumers keep a tight grip on their wallets.

"Considerable volume declines in turkey exports resulted in

lower volumes compared to the prior year," Hormel said in a

statement.

In recent quarters, price hikes have weakened volume

growth for salty snacks across the U.S., hurting sales of

companies like Hormel, Campbell's and PepsiCo ( PEP ).

Hormel has flagged a hit from a production disruption which

has been ongoing since the last quarter at its facility in

Suffolk, Virginia, due to a food safety issue. This has lowered

production of its Planters snack nuts.

The company expects fiscal year 2025 sales between $11.9

billion and $12.2 billion, compared with analysts' expectation

of 12.23 billion, according to data compiled by LSEG.

Hormel also expects adjusted profit of $1.58 to $1.72 per

share, the mid-point of which is below estimates of $1.68 per

share.

Excluding one-off items, the company earned 42 cents per

share in the fourth quarter while sales fell 2% to $3.14

billion.

Sales in Hormel's international segment rose 1%,

benefiting from growing demand in China after several quarters

of weakness.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Icahn Enterprises Strikes Open Market Sales Pact with Jefferies
Icahn Enterprises Strikes Open Market Sales Pact with Jefferies
Aug 26, 2024
08:50 AM EDT, 08/26/2024 (MT Newswires) -- Icahn Enterprises L.P ( IEP ) entered into an open market sales agreement with Jefferies (JEF) under which Icahn ( IEP ) may issue and sell its depositary units with an aggregate offering amount of up to $400 million, according to an SEC filing Monday. Shares of the company fell 1% in premarket...
Sector Update: Consumer
Sector Update: Consumer
Aug 26, 2024
08:50 AM EDT, 08/26/2024 (MT Newswires) -- Consumer stocks were rising in Monday's premarket hours with the Consumer Staples Select Sector SPDR Fund (XLP) 0.1% higher and the Consumer Discretionary Select Sector SPDR Fund (XLY) up 0.2% recently. PDD Holdings Inc ( PDD ) shares fell 18% after it reported a Q2 revenue of 97.06 billion Chinese renminbi ($13.63 billion),...
Columbia Financial Receives Regulatory Approval for Freehold Bank, Columbia Bank Merger
Columbia Financial Receives Regulatory Approval for Freehold Bank, Columbia Bank Merger
Aug 26, 2024
08:49 AM EDT, 08/26/2024 (MT Newswires) -- Columbia Financial ( CLBK ) said Monday that it received regulatory approval for Columbia Bank's merger with Freehold Bank from the US Office of the Comptroller of the Currency. The merger of Columbia Financial's ( CLBK ) subsidiaries is slated to close on Oct. 5, the holding company said. The company's shares were...
Vericel Says US FDA Approves sBLA for Tissue Restoring Knee Repair Treatment - Shares Up Pre-Bell
Vericel Says US FDA Approves sBLA for Tissue Restoring Knee Repair Treatment - Shares Up Pre-Bell
Aug 26, 2024
08:51 AM EDT, 08/26/2024 (MT Newswires) -- Vericel ( VCEL ) said Monday that the US Food and Drug Administration has approved its supplemental Biologics License Application, which expands the indications for its collagen membrane treatment MACI to include repair of symptomatic cartilage defects in the knee up to 4 square centimeters in size. The company said MACI, which is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved